New! Sign up for our free email newsletter.
Science News
from research organizations

New strategy against osteoporosis

Date:
August 5, 2020
Source:
University of Würzburg
Summary:
An international research team has found a new approach that may be able to reduce bone loss in osteoporosis and maintain bone health.
Share:
FULL STORY

Osteoporosis is the most common age-related bone disease which affects hundreds of millions of individuals worldwide. It is estimated that one in three women and one in five men aged over 50 suffer from osteoporotic bone fractures.

Osteoporosis is caused by excessive activity of bone resorbing cells, while activity of bone-forming cells is reduced. In healthy individuals, a balanced activity of these two cell types allows constant bone turnover to maintain healthy and strong bones.

In osteoporosis, disproportionate bone resorption leads to low bone mineral density and consequently weak and fracture-prone bones. When new bone formation is unable to catch up with bone loss, bone eventually weakens, and becomes more prone to fractures.

Current medicines have disadvantages

Most current osteoporosis therapies include the use of bisphosphonates, which block the activity of bone resorbing cells, and thus prevent excessive bone resorption. However, prolonged treatment with these drugs eliminates the necessary bone turn-over leading to increased fracture risk and other unwanted side effects. Therefore, there is an urgent need to develop new strategies that overcome the limitations of current treatments.

There are now new progresses in this area. They have been developed in a cooperation of Professors Christoph Winkler (Department of Biological Sciences, National University of Singapore, NUS) and Manfred Schartl (Biocenter, Julius-Maximilians-Universität Würzburg, JMU, Germany); the results have been published in the journal PNAS.

Small protein mobilises bone resorbing cells

Using genetic analysis in a small laboratory fish model, the Japanese medaka (Oryzias latipes), the research team identified a small protein, the chemokine CXCL9, that, under osteoporotic conditions, diffuses towards reservoirs that hold bone resorbing cell precursors. These precursors produce a receptor, CXCR3, on their cell surface. Upon activation by CXCL9, the precursors are mobilised and migrate long distances in a highly directed fashion towards the bone matrix, where they start resorbing bone.

Known inhibitors are highly effective

Both CXCL9 and its receptor CXCR3 have long been known to modulate the migration of immune cells to inflammation sites, for example in psoriasis and rheumatoid arthritis. There are several chemical inhibitors blocking CXCR3 activity that have had little success in clinical tests for the treatment of psoriasis. The research team showed that these inhibitors are highly effective in blocking bone resorbing cells' recruitment and protecting bone from osteoporotic insult.

Finely tuned therapies seem possible

The conclusion of the professors Schartl and Winkler: "Our studies provided new avenues to osteoporosis therapy. The new strategy allows a fine-tuned modulation of osteoclast numbers that are recruited to bone matrix rather than a widespread blockage of osteoclast activity as in traditional therapies. This has major advantages as excessive bone resorption can be prevented in a targeted manner but normal bone turn-over will still continue. This offers potential to avoid increased fracture risks in osteoporosis patients and to maintain healthy bone for improved quality of life."

Christoph Winkler is an alumnus of JMU. He was a PhD student and research assistant in Manfred Schartl's team and followed the call for a professorship in Singapore in 2007. He returned to JMU for a while in 2016 -- for a sabbatical, financially supported by the Würzburg University Board. During this time, the ground was prepared for the cooperation the results of which can now be read in PNAS.


Story Source:

Materials provided by University of Würzburg. Original written by Robert Emmerich. Note: Content may be edited for style and length.


Journal Reference:

  1. Quang Tien Phan, Wen Hui Tan, Ranran Liu, Sudha Sundaram, Anita Buettner, Susanne Kneitz, Benedict Cheong, Himanshu Vyas, Sinnakaruppan Mathavan, Manfred Schartl, Christoph Winkler. Cxcl9l and Cxcr3.2 regulate recruitment of osteoclast progenitors to bone matrix in a medaka osteoporosis model. Proceedings of the National Academy of Sciences, 2020; 202006093 DOI: 10.1073/pnas.2006093117

Cite This Page:

University of Würzburg. "New strategy against osteoporosis." ScienceDaily. ScienceDaily, 5 August 2020. <www.sciencedaily.com/releases/2020/08/200805102032.htm>.
University of Würzburg. (2020, August 5). New strategy against osteoporosis. ScienceDaily. Retrieved April 14, 2024 from www.sciencedaily.com/releases/2020/08/200805102032.htm
University of Würzburg. "New strategy against osteoporosis." ScienceDaily. www.sciencedaily.com/releases/2020/08/200805102032.htm (accessed April 14, 2024).

Explore More

from ScienceDaily

RELATED STORIES